Logo for CNS Pharmaceuticals Inc

CNS Pharmaceuticals Investor Relations Material

Latest events

Logo for CNS Pharmaceuticals Inc

Investor Update

CNS Pharmaceuticals
Logo for CNS Pharmaceuticals

Investor Update

11 Dec, 2024
Logo for CNS Pharmaceuticals

Q3 2024

14 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from CNS Pharmaceuticals Inc

Access all reports
CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company engaged in the development of anti-cancer drug candidates. Its primary focus is on treatments for primary and metastatic cancers of the brain and central nervous system malignancies. The company's flagship drug candidate, Berubicin, is a novel anthracycline, notable for being the first of its kind to cross the blood-brain barrier. This drug is currently in development for the treatment of glioblastoma multiforme (GBM), a particularly aggressive and currently incurable form of brain cancer. In addition to Berubicin, CNS Pharmaceuticals is advancing WP1244, a drug technology that leverages anthracycline and distamycin-based scaffolds to create potent small molecule agents. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.